Dr Reddy’s, Zydus, Cipla, Sun can sustain low-double digit EPS growth over medium term: Bino Pathiparampil
Indian pharma companies like Dr Reddy’s, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.
PharmaTimes23h
Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...